This is a modest portfolio expansion into a new patient segment (earlier-stage chronic swelling) via a VA/DoD-exclusive channel. The $3M upfront is small relative to the $673M market cap. Monitor for initial sales traction and reimbursement progress in the VA/DoD system over the next 2-3 quarters.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $29.04entry
- T+1 · 4mo ago −4.89%α −5.24% · $27.62
- T+5 · 4mo ago −1.03%α −0.25% · $28.74
- T+20 · 3mo ago +0.34%α −2.84% · $29.14
- T+60 · 6w ago −23.59%α −27.58% · $22.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a wearable non-pneumatic compression device, targeting VA and DoD patients. The company made a $3 million upfront payment and committed to minimum purchase obligations, expanding its chronic swelling portfolio into earlier-stage disease.
Key Facts
- Exclusive U.S. distribution rights for MyoSleeve within VA and DoD systems
- Upfront payment of $3 million to ElastiMed
- MyoSleeve is FDA 510(k) cleared for chronic swelling, lymphedema, and venous insufficiency
- Device uses electroactive polymer technology, is battery-powered, and operates without tubing or external controller
- Expands Tactile Medical's portfolio into earlier stages of chronic swelling, complementing existing pneumatic compression devices
Financial Impact
$3 million upfront payment plus undisclosed minimum purchase obligations and marketing commitments
Risk Factors
- Minimum purchase obligations could pressure cash flow if adoption is slow
- VA/DoD sales cycles are long and unpredictable
- MyoSleeve is a complementary product, not a replacement for core pneumatic devices, revenue contribution may be limited
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082947 |
| Document: tm2620304d1_ex99-1.htm | 0001104659-26-082947 |
| Document: 0001104659-26-082947-index-headers.html | 0001104659-26-082947 |
| Document: 0001104659-26-082947-index.html | 0001104659-26-082947 |
| Document: 0001104659-26-082947.txt | 0001104659-26-082947 |
Track record
17 reports on TCMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.99 Now $26.37 −2.30% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $27.11 Now $26.37 −2.73% settles Feb 12
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $26.62 Now $26.37 −0.94% settles Feb 8
- Nov 6, 202610d ago 3 Neutral 2/10 Entry $26.59 Now $26.37 −0.83% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago Press Release Bearish 5/10 No price data
- Nov 2, 202614d ago 8-K Mixed 5/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Oct 19, 202628d ago Press Release Neutral 3/10 Entry $23.52 Now $26.37 +12.12% settles Jan 15
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers